Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease (CKD) and end stage kidney failure worldwide. DKD develops in approximately 40% of patients with diabetes (1). In 2022, an estimated 828 million adults had diabetes, and the number continues to rise (2). A relatively new class of therapeutic agents, sodium–glucose cotransporter 2 (SGLT2) inhibitors, which were originally developed to improve glucose control by promoting glucosuria, have demonstrated powerful kidney a...
